Pangenomic Health Inc.
Symbol: NARA.CN
CNQ
0.08
CADTržní cena dnes
-0.5178
Poměr P/E
0.0003
Poměr PEG
0.77M
MRK Cap
- 0.00%
Výnos DIV
Pangenomic Health Inc. (NARA-CN) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0.1 | 1.3 | 0 | ||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.net-receivables | 0 | 0.2 | 0 | 0.1 | ||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-current-assets | 0 | 0.2 | 0.3 | 0 | ||||
balance-sheet.row.total-current-assets | 0 | 0.5 | 1.7 | 0.1 | ||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.intangible-assets | 0 | 0 | 0.8 | 0 | ||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0.8 | 0 | ||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0.9 | 0 | ||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-assets | 0 | 0.5 | 2.6 | 0.1 | ||||
balance-sheet.row.account-payables | 0 | 0.4 | 0.2 | 0 | ||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0 | 0 | ||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||
balance-sheet.row.other-current-liab | 0 | 0.2 | 0.2 | 0.1 | ||||
balance-sheet.row.total-non-current-liabilities | 0 | 0.5 | 0 | 0 | ||||
balance-sheet.row.other-liabilities | 0 | -0.5 | 0 | 0 | ||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-liab | 0 | 0.7 | 0.3 | 0.1 | ||||
balance-sheet.row.preferred-stock | 0 | 0 | 0.5 | 0 | ||||
balance-sheet.row.common-stock | 0 | 11.2 | 4.6 | 0.2 | ||||
balance-sheet.row.retained-earnings | 0 | -15 | -3 | -0.3 | ||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3.5 | 0.1 | 0.1 | ||||
balance-sheet.row.other-total-stockholders-equity | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-stockholders-equity | 0 | -0.2 | 2.2 | 0 | ||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 0.5 | 2.6 | 0.1 | ||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-equity | 0 | -0.2 | 2.2 | 0 | ||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||
Total Investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-debt | 0 | 0.1 | 0 | 0 | ||||
balance-sheet.row.net-debt | 0 | 0 | -1.3 | 0 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -12 | -2.6 | -0.1 | ||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||
cash-flows.row.deferred-income-tax | 0 | 0 | 1.8 | 0 | ||||
cash-flows.row.stock-based-compensation | 0 | 0.6 | 0.1 | 0 | ||||
cash-flows.row.change-in-working-capital | 0 | 0.2 | -0.3 | 0.1 | ||||
cash-flows.row.account-receivables | 0 | -0.1 | 0 | 0 | ||||
cash-flows.row.inventory | 0 | 0.1 | 0 | 0 | ||||
cash-flows.row.account-payables | 0 | 0.2 | 0.1 | 0 | ||||
cash-flows.row.other-working-capital | 0 | 0 | -0.3 | 0.1 | ||||
cash-flows.row.other-non-cash-items | 0 | 8.4 | 0 | 0 | ||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-investing-activites | 0 | 0 | -0.6 | -0.1 | ||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -0.1 | -0.6 | -0.1 | ||||
cash-flows.row.debt-repayment | 0 | -0.1 | 0 | 0 | ||||
cash-flows.row.common-stock-issued | 0 | 1.3 | 2.5 | 0.1 | ||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-financing-activites | 0 | 0.4 | 0.5 | 0 | ||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 1.6 | 3 | 0.2 | ||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||
cash-flows.row.net-change-in-cash | 0 | -1.3 | 1.3 | 0 | ||||
cash-flows.row.cash-at-end-of-period | 0 | 0.1 | 1.3 | 0 | ||||
cash-flows.row.cash-at-beginning-of-period | 0 | 1.3 | 0 | 0 | ||||
cash-flows.row.operating-cash-flow | 0 | -2.8 | -1.1 | 0 | ||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||
cash-flows.row.free-cash-flow | 0 | -2.8 | -1.1 | 0 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.research-development | 0 | - | - | - | ||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.operating-expenses | 0 | 3.6 | 0.9 | 0.1 | ||||
income-statement-row.row.cost-and-expenses | 0 | 3.6 | 0.9 | 0.1 | ||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.total-other-income-expensenet | 0 | -8.4 | -1.8 | 0 | ||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.total-operating-expenses | 0 | -8.4 | -1.8 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||
income-statement-row.row.operating-income | 0 | -3.6 | -0.9 | -0.1 | ||||
income-statement-row.row.income-before-tax | 0 | -12 | -2.6 | -0.1 | ||||
income-statement-row.row.income-tax-expense | 0 | 8.4 | 0 | 0 | ||||
income-statement-row.row.net-income | 0 | -20.3 | -2.7 | -0.1 |
Často kladené otázky
Co je Pangenomic Health Inc. (NARA.CN) celková aktiva?
Pangenomic Health Inc. (NARA.CN) celková aktiva jsou 504142.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.000.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -0.016.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.000.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.000.
Co je Pangenomic Health Inc. (NARA.CN) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je -20347972.000.
Jaký je celkový dluh podniku?
Celkový dluh je 101771.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 3641827.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.